Equities analysts expect Luminex Co. (NASDAQ:LMNX) to announce $77.75 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Luminex’s earnings, with the highest sales estimate coming in at $78.54 million and the lowest estimate coming in at $77.27 million. Luminex posted sales of $78.20 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 0.6%. The firm is expected to issue its next quarterly earnings report on Monday, February 11th.

On average, analysts expect that Luminex will report full-year sales of $312.95 million for the current fiscal year, with estimates ranging from $311.95 million to $315.00 million. For the next year, analysts anticipate that the firm will report sales of $326.85 million, with estimates ranging from $305.00 million to $358.52 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Luminex.

Luminex (NASDAQ:LMNX) last announced its quarterly earnings data on Monday, November 5th. The medical instruments supplier reported $0.05 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.03). The company had revenue of $72.40 million during the quarter, compared to the consensus estimate of $74.05 million. Luminex had a return on equity of 5.99% and a net margin of 5.65%. The business’s revenue was down 2.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.13 EPS.

LMNX has been the topic of several research reports. Citigroup lifted their price objective on shares of Luminex from $23.00 to $34.00 and gave the stock a “$33.58” rating in a research report on Monday, July 23rd. Zacks Investment Research downgraded shares of Luminex from a “hold” rating to a “sell” rating in a research note on Wednesday, August 8th. ValuEngine downgraded shares of Luminex from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 8th. BidaskClub downgraded shares of Luminex from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 22nd. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $27.00 target price on shares of Luminex in a research note on Tuesday, August 7th. Five analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $28.40.

LMNX stock traded down $0.47 during mid-day trading on Wednesday, hitting $26.61. The company had a trading volume of 306,857 shares, compared to its average volume of 300,699. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of 29.24, a P/E/G ratio of 3.26 and a beta of 0.34. Luminex has a 12 month low of $18.62 and a 12 month high of $35.37.

The firm also recently announced a quarterly dividend, which was paid on Friday, October 12th. Stockholders of record on Friday, September 21st were paid a $0.06 dividend. The ex-dividend date was Thursday, September 20th. This represents a $0.24 annualized dividend and a dividend yield of 0.90%. Luminex’s payout ratio is 26.37%.

Several institutional investors and hedge funds have recently bought and sold shares of LMNX. Raymond James Financial Services Advisors Inc. purchased a new position in Luminex during the second quarter valued at approximately $207,000. Crossmark Global Holdings Inc. purchased a new position in Luminex during the second quarter valued at approximately $214,000. Cubist Systematic Strategies LLC grew its stake in Luminex by 7,572.6% during the second quarter. Cubist Systematic Strategies LLC now owns 7,289 shares of the medical instruments supplier’s stock valued at $215,000 after acquiring an additional 7,194 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in Luminex during the third quarter valued at approximately $227,000. Finally, OppenheimerFunds Inc. purchased a new position in Luminex during the second quarter valued at approximately $231,000. Hedge funds and other institutional investors own 82.36% of the company’s stock.

Luminex Company Profile

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.

See Also: Hedge Funds – Risk or Reward?

Get a free copy of the Zacks research report on Luminex (LMNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.